Compare Enveric Biosciences Inc (ENVB) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Sunrun Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Sunrun Inc trades at $7.64 (market cap $1.83B). The key difference: Sunrun Inc is far larger — about 269.1× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 8,672,852). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Sunrun Inc for 16 Days on average.
| ENVB | RUN | |
|---|---|---|
Market Cap | $6.80M | $1.83B |
Volume | 64,867 | 8,672,852 |
Sector | Health | Energy |
52-Week High | $10.80 | $21.41 |
52-Week Low | $1.27 | $7.59 |
Typical Hold Time | 14 Days | 16 Days |
Enterprise Value | -$1.49M | $16.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% today, with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and ROA at -193.53%, though it has consistently beaten EPS estimates in recent quarters. Recent positive developments include new patent allowances and preclinical data supporting its non-hallucinogenic drug candidates.
The outlook remains speculative given the lack of revenue and negative cash flow from operations, offset by strong analyst buy ratings (75%). Key risks include clinical trial outcomes and funding needs, while catalysts hinge on regulatory progress and successful drug development in the competitive biotech space.
Sunrun (RUN) trades at $7.64, up 0.39% with a bearish technical outlook despite strong analyst support. The company shows mixed fundamentals with revenue growth to $3.5B in 2026 but declining net margins from 15.21% to 11.59%. Recent partnerships with SPAN and Tesla highlight innovation, but negative operating cash flow and high debt-to-asset ratio of 70.76% pose challenges.
The stock presents a value opportunity with low P/E (5.16) and P/B (0.52) ratios, supported by a $16.33 consensus price target. However, risks include persistent cash burn, solar industry headwinds from high borrowing costs, and volatile sentiment. Investors should weigh cheap valuation against execution risks in a capital-intensive sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
